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Summary
The concept of specific chemotherapy was developed a century ago by Paul Ehrlich and others.
Dyes and arsenical compounds that displayed selectivity against trypanosomes were central to this
work 1,2, and the drugs that emerged remain in use for treating Human African Trypanosomiasis
(HAT) 3. Ehrlich recognised the importance of understanding the mechanisms underlying
selective drug action and resistance for the development of improved HAT therapies, but these
mechanisms have remained largely mysterious. Here, we use all five current HAT drugs for
genome-scale RNA interference (RNAi) target sequencing (RIT-seq) screens in Trypanosoma
brucei, revealing the transporters, organelles, enzymes and metabolic pathways that function to
facilitate anti-trypanosomal drug action. RIT-seq profiling identifies both known drug
importers 4,5 and the only known pro-drug activator 6, and links more than fifty additional genes to
drug action. A specific bloodstream stage invariant surface glycoprotein (ISG75) family mediates
suramin uptake while the AP-1 adaptin complex, lysosomal proteases and major lysosomal
transmembrane protein, as well as spermidine and N-acetylglucosamine biosynthesis all contribute
to suramin action. Further screens link ubiquinone availability to nitro-drug action, plasma
membrane P-type H+-ATPases to pentamidine action, and trypanothione and multiple putative
kinases to melarsoprol action. We also demonstrate a major role for aquaglyceroporins in
pentamidine and melarsoprol cross-resistance. These advances in our understanding of
mechanisms of anti-trypanosomal drug efficacy and resistance will aid the rational design of new
therapies and help to combat drug resistance, and provide unprecedented levels of molecular
insight into the mode of action of anti-trypanosomal drugs.
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African trypanosomes are transmitted by the tsetse insect vector and circulate in the
bloodstream and tissue fluids of their mammalian hosts. These protozoan parasites cause
Human African Trypanosomiasis (HAT), also known as sleeping sickness, and the livestock
disease known as Nagana. HAT is typically fatal without chemotherapeutic intervention.
The public health situation has improved recently with increased monitoring and
chemotherapy averting more than 1.3 million DALYs (Disability-Adjusted Life Years)
during 2000 and cases estimated at less than 70,000 in 2006 7. However, therapies suffer
multiple problems including severe toxicity and increasing resistance, a major concern due
to the absence of a vaccine or therapeutic alternatives 3. The current HAT therapies are
pentamidine or suramin, which are only suitable for the first stage of the disease prior to
central nervous system involvement, and eflornithine, nifurtimox or melarsoprol for
advanced disease 3 (Supplementary Table 1). Developed well before the advent of
molecular, target-based therapy, all of these drugs, except for eflornithine, elicit their anti-
trypanosomal effects by disrupting unknown targets. Increasing HAT treatment failure rates
were reported for suramin, when this drug was still in use in West Africa in the 1950s 8,
while melarsoprol treatment failure is a current and increasing problem 9.
We used genome-scale tetracycline-inducible RNA interference (RNAi) library screens in
Trypanosoma brucei to identify the genes that contribute to drug action. In these screens,
knockdowns only persist in an otherwise toxic environment if they confer a selective
advantage while others are diminished or eliminated (Fig. 1a); note that knockdown is not
expected to identify drug targets. The RNAi library consists of ~750,000 clones, each
transformed with one RNAi construct, and representing >99% of the approximately 7,500
non-redundant T. brucei gene set. Because each gene is identified by an average of
approximately five different RNAi sequences, true leads can be identified with high
confidence and potential off-target false leads can be minimised (see Supplementary
Methods). Screens were performed using all current HAT drugs and each yielded a
population of cells displaying an inducible drug resistance phenotype after eight or fourteen
days of selection (Fig. 1b and Supplementary Fig. 1). Genomic DNA from these cells was
subjected to RNAi target sequencing (RIT-seq) 10 to create profiles of RNAi targets
associated with increased resistance, and to identify the genes that contribute to drug
susceptibility. Genome-wide association maps show read-density for 7,435 T. brucei genes
(Fig. 1c). We defined genes with ‘primary signatures’ as those associated with two or more
independent RIT-seq tags, each with a read-density of >99; the screens yielded 55 of these
signatures (red bars in Fig. 1c; see Supplementary Methods and Supplementary data File 1).
Previous work linked the P2 adenosine transporter (AT1) to melarsoprol uptake 4,11-13, an
amino acid transporter (AAT6) to eflornithine uptake 5,13,14 and a nitroreductase (NTR) to
nifurtimox activation 6,14. Each of these genes is identified on the appropriate genome-wide
association map (Fig. 1c), providing validation for our screens and indicating excellent
genome-scale coverage in the RNAi library. Selected read-density signatures that establish
new genetic links to drug susceptibility are shown in Figure 1d.
The known eflornithine transporter is the only primary signature from the eflornithine
screen. In striking contrast, the suramin screen revealed twenty-eight genes associated with
primary signatures (Fig. 1c and Supplementary data File 1). Suramin, used for HAT therapy
since the 1920s 15, is a colourless sulphated napthylamine related to Ehrlich’s trypan red.
This drug cannot cross lipid membranes by passive diffusion due to strong negative charge.
Genes linked to suramin action encode a bloodstream stage-specific invariant surface
glycoprotein (ISG75) of unknown function 16, four lysosomal proteins (the CatL and CBP1
peptidases, p67 and Golgi/lysosomal protein-1, GLP-1), all four subunits of the adaptin
complex (AP) 1, involved in endosomal, clathrin-mediated trafficking, and multiple
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spermidine and N-acetylglucosamine (NAG) biosynthetic enzymes (Supplementary Fig. 2
and Supplementary data File 1).
Eight of these genes were selected for further analysis. We assembled multiple independent
inducible RNAi strains for each gene and confirmed that knockdown (Fig. 2a,
Supplementary Fig. 3) increased suramin resistance in every case (Fig. 2b, Supplementary
Fig. 4). We then determined subcellular localisation for the putative major facilitator
superfamily transporter (MFST); the MFST gene gave the strongest read-density signature in
the suramin screen and the greatest effective 50% inhibitory concentration (EC50) increase
(>10-fold) following knockdown (Fig. 2b). MFST, and a member of the endo-membrane
protein 70 family (EMP70), in contrast to UbH1, partitioned into the T. brucei membrane
fraction, as expected (Fig. 2c), and MFST localised to the lysosome, along with the major
lysosomal type I membrane glycoprotein, p67 17, also identified in the screen (Fig. 2d).
Because ISG75 trafficking is ubiquitin-dependent 18 we investigated whether UbH1, a
putative ubiquitin hydrolase identified by the screen, influenced ISG75 expression. UbH1
knockdown reduced ISG75 but not ISG65 expression (Fig. 2e), suggesting that
deubiquitination by UbH1 specifically affects ISG75 copy number; clearly this mimics the
direct effect of RNAi against ISG75. A vacuolar protein sorting factor, Vps5, that positively
controls ISG75 expression 19, and a second putative ubiquitin hydrolase, were also identified
by the screen (see Supplementary Fig. 2 and Supplementary data File 1), suggesting that
ISG75 copy number is highly connected to suramin resistance. To ask if ISG75 contributes
to suramin binding, we performed whole-cell binding-assays using 3[H]-labelled suramin.
Cells depleted for ISG75 displayed significantly and specifically reduced suramin binding
(Fig. 2f).
We observed >4-fold increase in EC50 following knockdown of the cathepsin-L (CatL) like
protease known as brucipain, another abundant lysosomal protein 20, and an orthogonal
assay using a dual-specificity CatL/CatB inhibitor revealed inhibitor antagonism (Fig. 2g),
indicating that protease activity enhances suramin toxicity. Taken together, the results
demonstrate a central role for lysosomal functions in suramin action. Since four enzymes
involved in spermidine biosynthesis, including ornithine decarboxylase (ODC), were linked
to suramin action (Supplementary data File 1), we used eflornithine to specifically inhibit
ODC, which again revealed inhibitor antagonism (Fig. 2g; see note b in Supplementary
Table 1). Thus, ODC activity enhances suramin toxicity, likely through spermidine
biosynthesis. Suramin endocytosis 21 and intralysosomal accumulation 22 have been
demonstrated previously in T. brucei. In addition, an acquired suramin resistance phenotype
was stable in bloodstream stage T. brucei but was not expressed in the insect stage 23. Our
RIT-seq profile, stage-specific expression of ISG75 16 and strong down-regulation of
endocytic and lysosomal activities in the insect stage 24, are all consistent with these
observations.
Paul Ehrlich’s work with dyes and arsenicals revealed the first examples of resistance to
chemotherapy a century ago and, based on cross-resistance, he deduced that there are shared
mechanisms contributing to the action of certain ‘parasitotropic’ compounds 1. Among
current HAT therapies, cross-resistance has been documented only for melarsoprol and
pentamidine 9 but our understanding of the mechanism remains incomplete. Both drugs
enter trypanosomes through the P2 adenosine transporter, but additional, dual-specificity
transporters are predicted 9. To identify cross-resistance mechanisms, we analysed all pair-
wise comparisons among our screens (Fig. 3a). A single robust signature emerged,
implicating two closely related aquaglyceroporins (AQPs) 25 in melarsoprol and
pentamidine cross-resistance. To directly test the role of the AQPs, we generated aqp2/3 null
strains (Fig. 3b). The EC50 for melarsoprol and pentamidine was increased >2-fold and >15-
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fold, respectively, in aqp2/3 null cells compared to wild-type (Fig. 3c). Our favoured
hypothesis involves regulation of dual-specificity transporters by AQPs.
The nifurtimox, pentamidine and melarsoprol screens yielded eight, nine and nine genes
associated with primary signatures, respectively. The major primary signature in the
nifurtimox profile identified the mitochondrial, flavin-dependent nitroreductase that
activates this class of nitro pro-drugs 6. We also identified the putative flavokinase which
converts riboflavin to FMN, an essential nitroreductase cofactor 6. Four additional signatures
identified genes encoding proteins linked to ubiquinone biosynthesis (Supplementary Fig. 2
and Supplementary data File 1), in support of the hypothesis that nitroreductase, like NADH
dehydrogenases, transfers electrons from NADH to ubiquinone (UQ-9) to generate
ubiquinol 6. We assembled RNAi strains for one of these factors and demonstrated that
knockdown increased the EC50 for nifurtimox by approximately 1.5-fold (Supplementary
Fig. 5). Thus, six gene signatures support a dominant role for nitroreductase in nifurtimox
activation and suggest that this is dependent upon the availability of the FMN cofactor and
the natural substrate.
Pentamidine is an aromatic diamidine, a nucleic acid binding drug that accumulates to
millimolar concentrations and collapses trypanosome mitochondrial membrane potential 26.
Two primary signatures from the pentamidine screen identify genes encoding P-type
ATPases (Supplementary Fig. 2 and Supplementary data File 1), and one of these represents
the plasma membrane H+-ATPases, HA1-3 27. We assembled RNAi strains for these
ATPases and demonstrated that knockdown increased the EC50 for pentamidine by >8-fold
(Supplementary Fig. 5), suggesting that an HA1-3 dependent proton motive force is required
to drive pentamidine uptake. We used a similar approach to demonstrate >2-fold increase in
the EC50 for pentamidine following knockdown of a putative protein phosphatase
(Supplementary Fig. 5).
Melarsoprol acts primarily by forming a stable adduct with trypanothione, known as Mel
T 28, but whether this adduct reduces or increases toxicity has remained unclear. The
melarsoprol screen identified a link to trypanothione synthase and trypanothione reductase
(Supplementary Fig. 2 and Supplementary data File. 1), suggesting that the Mel T adduct is
toxic. Three other primary signatures identified an over-representation (P=2.3×10−9, χ2 test)
of putative protein kinases (Supplementary Fig. 2 and Supplementary data File. 1) while
another signature identified a gene encoding a highly phosphorylated protein related to the
N-terminal segment of the LArge Tumor Suppressor, LATS1 (see Supplementary Fig. 2a).
We used independent strains to confirm that LATS1-like knockdown increased the EC50 for
melarsoprol by approximately 1.5-fold (Supplementary Fig. 5). Based on these signatures,
we suggest a role for a signalling cascade in melarsoprol susceptibility. Our findings are
summarised in Figure 4. In particular, we propose suramin uptake via ISG75-mediated
endocytosis (Fig. 4a). Metabolic pathways that contribute to suramin or nifurtimox action
are detailed in Figure 4b.
All but one of the current HAT drugs was developed in the absence of an understanding of
the chemical-biological relationships underlying toxicity or selectivity. Our RIT-seq profiles
revealed more than fifty T. brucei genes that enhance drug susceptibility, unearthing
interactions that are largely inaccessible using other approaches. Notably, the knockdown
approach and the sensitivity of RIT-seq allow access to essential proteins, complexes and
pathways, such as the H+-ATPase, the adaptin complex and spermidine biosynthesis. Our
results also illustrate the utility of drugs as molecular probes for functional networks. In
particular, the findings highlight factors that contribute to drug accumulation or the
generation of toxic metabolites, features that could be exploited to deliver or generate novel
toxins. Additionally, absence or loss of function could explain innate or acquired resistance;
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suramin or melarsoprol/pentamidine resistance may be due to reduced MFST or AQP
expression, respectively, for example (Supplementary Fig. 6). These advances in our
understanding of drug-trypanosome interactions will facilitate rational approaches to the
design of more efficacious and durable therapies, and for monitoring the emergence and
spread of resistance.
METHODS SUMMARY
Assembly of the bloodstream-form T. brucei RNAi library and RNAi target sequencing
(RIT-seq) were reported previously 10. Briefly, a tetracycline-inducible RNAi plasmid
library, containing randomly sheared genomic fragments (mean ~600 bp) under the control
of head-to-head, tetracycline-inducible phage T7 promoters 29, was targeted to a single
genomic locus that had been validated for robust expression 30. The long double-stranded
RNAs generated in the presence of tetracycline are processed to produce a pool of small-
interfering RNAs that programme the endogenous RNAi machinery to mediate sequence-
specific destruction of the cognate mRNA. For this study, the library was grown under
inducing conditions with drug selection and genomic DNA was isolated from surviving
populations. For RIT-seq profiling, adapter-ligated sequencing libraries were prepared from
each genomic DNA sample and used to amplify DNA fragments containing RNAi cassette-
insert junctions in semi-specific PCR reactions; one primer was specific for the RNAi vector
and the other for the Illumina adapter. Size-selected DNA was sequenced with 76 cycle runs
on an Illumina GAII. Sequencing reads containing a nine-base RNAi cassette-insert junction
sequence were then mapped to the T. brucei reference genome. Where loss of function
increases drug tolerance, RNAi-target sequence representation is increased relative to the
otherwise susceptible population, revealing ‘hot spots’. Thus, RNAi target fragments serve
as templates for the production of dsRNA and also provide unique sequence identifiers for
each clonal population.
METHODS
T. brucei growth and drug selection
The bloodstream-form T. brucei MiTat 1.2, clone 221a RNAi library 10 was derived using
the randomly sheared genomic fragment (mean ~600 bp) RNAi plasmid library 29. The T.
brucei RNAi library and 2T1 cells 30 were maintained as described. For selective screens,
the RNAi library, maintained throughout at >5×106 cells, was induced with tetracycline
(Tet; 1 μg ml−1) for 24 h and then grown in medium containing Tet, plus each HAT drug at
0.5 to 3.5 × EC50 (Supplementary Table 1; Supplementary Fig. 1); all drug stocks were in
DMSO.
RNAi target sequencing (RIT-seq)
Selected populations from each screen were assessed for Tet-dependent drug-resistance. The
RNAi target fragments provide unique identifiers for each clone in the population. As a
quality-control step, PCR amplification, agarose gel fractionation and Sanger sequencing of
the eluted products were performed as described 14, followed by RIT-seq analysis 10; all
nine genes identified by Sanger sequencing were associated with high-density Illumina read-
counts (13,000 to 528,000; see Supplementary data File 1a). Briefly, we ran 76 cycle
sequencing on an Illumina GAII; this generates sequence tags derived from the ends of the
RNAi target fragments. Only sequences containing a terminal RNAi-vector junction
sequence (GCCTCGCGA) were mapped to the T. brucei 927 reference genome 31 using the
SSAHA sequence alignment algorithm 32. After mapping, we obtained, for each protein
coding sequence (CDS) in each experiment, a count of reads mapping; all genes associated
with >9 reads are detailed in Supplementary data File 1b. We also browsed all read-density
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plots in Artemis 33 for signatures that fell outside of CDSs to generate the full non-
redundant ‘hit-list’ detailed in Supplementary data File 1a.
Read-density signatures
Genome coverage in the current RNAi library represents >99% of all genes, with 5 RNAi
targets per gene on average 10; shorter genes are expected to be represented by fewer RNAi
targets. Our screens yielded 5 to 59 genes (0.07 – 0.8 %) with a >99RIT-seq tag (a tag with a
read density of >99; eflornithine, 5; suramin, 59; nifurtimox, 54; pentamidine, 17 and
melarsoprol, 19). In each screen, at least one gene was associated with a >50,000RIT-seq tag
(Supplementary data File 1a). From this set, we derived 55 genes with ‘primary signatures’,
those associated with two or more >99RIT-seq tags. If these tags were randomly distributed,
we would expect a single primary signature from 300 screens using eflornithine or from two
screens using suramin, assigning a high degree of confidence to the vast majority of
observed primary signatures (Supplementary data File 1a). The nifurtimox output is unusual
compared to the other outputs and may reflect drug-mediated mutagenesis 34; inactivating
mutations within NTR, for example, may prolong the survival of clones carrying unrelated
RNAi targets. However, even limited Tet-regulated drug resistance (Fig. 1b) and a high
number of sequence tags in the nifurtimox screening profile (Supplementary data File 1 and
black bars in Fig. 1c) had little impact on primary signature confidence. Many of the 130
genes associated with ‘secondary signatures’ in Supplementary data File 1a may also reflect
mechanisms of drug action, but we only considered seven of these genes here that were
linked to a common function with a primary hit (Supplementary Fig. 2). We observe 3.5 tags
per gene on average associated with the 24 primary, single copy genes shown in
Supplementary Figure 2. Minimal library propagation could explain a modest reduction in
coverage but we suggest that reduced coverage in the current RIT-seq outputs is primarily
explained by major fitness defects following knockdown.
Plasmid construction and strain assembly
The AQP locus was disrupted by replacement of a 4,772 bp (aqp2/aqp3) fragment with NPT
and BLA selectable markers (the T. brucei genome is diploid). Gene-specific RNAi
fragments of 400-600 bp, or 200 bp to facilitate moderate knockdown in the case of the
known essential gene p67 17, were amplified using PCR primers designed using RNAit 35
and cloned into pRPaiSL for the generation of stem-loop, ‘hairpin’ dsRNA as the trigger for
RNAi 36. We used a long, 400-600 bp RNAi target fragment for CatL because RNAi
previously produced no growth defect 37. However, cells retained 35% CatL activity in that
study, likely explaining why we see a major growth defect when expressing a more potent
stem-loop dsRNA (Supplementary Fig. 3). For epitope tagging at native loci, C-terminal
fragments, or an N-terminal fragment (UbH1), were amplified and cloned in pNATxTAG or
pNATTAGx 36, respectively. Constructs were introduced into 2T1 cells as described 30. Full
oligonucleotide details are available on request.
Strain analysis
Cumulative growth curves were generated from cultures seeded at 105 cells ml−1, counted
on a haemocytometer and diluted back to 105 cells ml−1 as necessary. For EC50 assays,
RNAi strains were pre-induced for 72 h in 1 μg ml−1 tetracycline, except CatL and AP-1β,
which were pre-induced for 24 h at 2.5 and 1 ng ml−1, respectively. Isobolograms were
generated using a checkerboard assay as described 38; FMK024 (N-Morpholineurea-
phenylalanyl-homophenylalanylfluoromethyl ketone, Sigma) is an irreversible, dual-
specificity inhibitor of CatL/CatB. All EC50 assays were carried out using alamarBlue as
described 14,39. Southern blotting was carried out according to standard procedures 40. Sub-
cellular fractionation by hypotonic lysis was carried out as described 41. All protein samples
were stored in the presence of a protease inhibitor cocktail (Roche) and were not boiled.
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Whole cell lysates and hypotonic lysis fractions were separated by SDS-PAGE using
standard protocols 40. Immunofluorescence was carried out as previously described 10. We
used specific antisera to detect ISG75 42, p67 43, CatL 17, GLP-1 44 and AP-1γ 45 while anti
MYC antisera were used to detect tagged versions of MFST, UbH1 and EMP70. To assess
suramin binding, cells were harvested at mid-log phase and resuspended at 107 ml−1 in 35
nM 3[H]-suramin (Hartmann Analytic; pre-incubated for 16 hours in complete HMI11) at
37°C. Cells were washed in ice cold PBS, resuspended in 100 μl Optiphase Supermix
scintillant (Perkin Elmer) and 3[H]-suramin incorporation quantified using a 1450 Microbeta
scintillation counter (Perkin Elmer).
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Figure 1. Identification of drug efficacy determinants in T. brucei
a, The schematic illustrates the RNAi library screening approach. Expected outcomes are
illustrated for RNAi targets that fail to affect drug resistance (black), increase resistance to
drug A (blue), drug B (orange) or both (green). b, Each screen yielded a population
displaying Tet-inducible (RNAi-dependent) drug-resistance; see Supplementary Fig. 1. The
plot indicates the proportion of the resistance phenotype that is Tet-inducible. c, Genome-
wide RIT-seq profiles. Each map represents a non-redundant set of 7,435 protein-coding
sequences. Red bars represent ‘primary’ read-density signatures. Black bars represent all
other signatures of >50 reads (see Supplementary data File 1). All three expected ‘hits’,
AAT6, AT1 and NTR, are indicated. d, Selected signatures. Each peak represents a unique
RIT-seq tag. ‘+’, numbers of additional genes identified in each category. See
Supplementary Figure 2 for details and additional signatures.
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Figure 2. A network of proteins link ISG75, endocytosis and lysosomal functions to suramin
action
a, Western blots demonstrate knockdown; Coomassie stains serve as loading controls. See
Supplementary Fig. 3 for growth curves. b, Endosomal/lysosomal factors and ISG75
contribute to suramin action. Error bars, s.d. from independent RNAi strains; see
Supplementary Fig. 4. c, MFST and EMP70 are membrane-associated. The western blots
show supernatant (S), wash (W) and pellet (P; membrane-fraction). d, MFST co-localises
with lysosomal protein, p67, but not recycling endosomes (Rab11). e, Knockdown of UbH1
specifically decreases ISG75 expression. f, ISG75 mediates suramin binding. Error bars, s.d.
from duplicate experiments. P value from Student’s t-test. ISG75 knockdown is shown.
Scale bar, 5 μm. g, CatL/CatB and ODC inhibitors, FMK024 and eflornithine, respectively,
antagonise suramin action. Isobolograms showing 50% fractional inhibitory concentrations
(FICs). The solid lines indicate antagonism. The dashed lines indicate expected outcomes
for no interaction.
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Figure 3. aqp2/3 null cells are melarsoprol, pentamidine cross-resistant
a, Analysis of read-density for all (74,350) possible pair-wise comparisons of a non-
redundant T. brucei gene set; E, eflornithine; M, melarsoprol; N, nifurtimox; P, pentamidine;
S, suramin; X and Y, axes representing each dataset. The box on the right shows the read-
density signatures for this locus (Tb927.10.14160-70). b, AQP2/3 knockout was confirmed
by Southern blotting. S, SacII; Δ, the region deleted; bars indicate probes. c, EC50 analysis
indicates melarsoprol, pentamidine cross-resistance in aqp2/3 null cells. Error bars, s.d. from
triplicate assays and independent null strains.
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Figure 4. Determinants of drug efficacy in African trypanosomes
Proteins and metabolites linked to drug action are identified by red and green text,
respectively. a, The schematic summarises the findings from the RIT-seq screens. In the
case of suramin, we propose that ISG75 binds the drug at the cell surface. ISG75 trafficking
then delivers the complex, via the flagellar pocket (FP), to the endosomal system, leading to
accumulation in the lysosome where the drug is liberated by proteases. The MFST may
deliver the drug to the cytosol. HAPT/LAPT, high/low-affinity pentamidine transporters;
TS2, oxidised trypanothione; T[SH]2, reduced trypanothione. b, Biosynthetic pathways
linked to drug action. See text and Supplementary data File 1 for acronyms and further
details.
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